GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (OTCPK:MMIRF) » Definitions » Return-on-Tangible-Asset

MedMira (MedMira) Return-on-Tangible-Asset : -52.77% (As of Jan. 2024)


View and export this data going back to . Start your Free Trial

What is MedMira Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. MedMira's annualized Net Income for the quarter that ended in Jan. 2024 was $-1.76 Mil. MedMira's average total tangible assets for the quarter that ended in Jan. 2024 was $3.34 Mil. Therefore, MedMira's annualized Return-on-Tangible-Asset for the quarter that ended in Jan. 2024 was -52.77%.

The historical rank and industry rank for MedMira's Return-on-Tangible-Asset or its related term are showing as below:

MMIRF' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -760.29   Med: -223.98   Max: -18.56
Current: -72.18

During the past 13 years, MedMira's highest Return-on-Tangible-Asset was -18.56%. The lowest was -760.29%. And the median was -223.98%.

MMIRF's Return-on-Tangible-Asset is ranked worse than
69.78% of 1552 companies
in the Biotechnology industry
Industry Median: -39.47 vs MMIRF: -72.18

MedMira Return-on-Tangible-Asset Historical Data

The historical data trend for MedMira's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira Return-on-Tangible-Asset Chart

MedMira Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -761.61 -111.85 -19.21 -46.69 -70.78

MedMira Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -52.91 -62.40 -104.07 -74.51 -52.77

Competitive Comparison of MedMira's Return-on-Tangible-Asset

For the Biotechnology subindustry, MedMira's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedMira's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MedMira's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where MedMira's Return-on-Tangible-Asset falls into.



MedMira Return-on-Tangible-Asset Calculation

MedMira's annualized Return-on-Tangible-Asset for the fiscal year that ended in Jul. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Jul. 2023 )  (A: Jul. 2022 )(A: Jul. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Jul. 2023 )  (A: Jul. 2022 )(A: Jul. 2023 )
=-2.026/( (2.961+2.764)/ 2 )
=-2.026/2.8625
=-70.78 %

MedMira's annualized Return-on-Tangible-Asset for the quarter that ended in Jan. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Jan. 2024 )  (Q: Oct. 2023 )(Q: Jan. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Jan. 2024 )  (Q: Oct. 2023 )(Q: Jan. 2024 )
=-1.76/( (3.345+3.326)/ 2 )
=-1.76/3.3355
=-52.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Jan. 2024) net income data.


MedMira  (OTCPK:MMIRF) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


MedMira Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of MedMira's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


MedMira (MedMira) Business Description

Traded in Other Exchanges
Address
155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.

MedMira (MedMira) Headlines

From GuruFocus

MedMira Closes New Equity Investment for Future Growth

By GlobeNewswire GlobeNewswire 07-15-2021

MedMira Announces Product Update

By GlobeNewswire GlobeNewswire 12-31-2020

MedMira Reports Third Quarter Results FY2021

By GlobeNewswire GlobeNewswire 06-30-2021

MedMira Reports First Quarter Results FY2024

By ACCESSWIRE 12-30-2023

Management Cease Trade Order Update

By GlobeNewswire GlobeNewswire 12-26-2018

MedMira Reports 2019 Fourth Quarter and Year End Financial Results

By GlobeNewswire GlobeNewswire 11-29-2019

MedMira Reports Third Quarter Results FY2023

By ACCESSWIRE 06-30-2023

MedMira Receives CE Mark for Its VYRA(TM) COVID-19 Antigen Test

By ACCESSWIRE ACCESSWIRE 10-14-2022